Clinical Trial Update: A Trial of Shengmai Liquid for Long COVID Fatigue. [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial evaluating Shengmai Liquid for fatigue in Long COVID (post-acute sequelae of SARS-CoV-2 infection) is currently recruiting in China.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Post-acute Sequelae of Sars-cov-2 Infection

Drugs mentioned

• Shengmai Liquid

Snippet

Sponsor: Beijing University of Chinese Medicine | Conditions: Long COVID Fatigue | Phase 4 | Status: RECRUITING